Aesthetics & SkinModerate EvidenceArgirelineAcetyl Hexapeptide-3

Topical Application of a Peptide Inhibitor of Hexapeptide Acetyl Hexapeptide-3 Reduces Wrinkle Depth

Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A

International Journal of Cosmetic Science · Vol. 24(5) · pp. 303–310 · 2002

Clinical and mechanistic study demonstrating that Argireline (acetyl hexapeptide-3) reduces wrinkle depth by inhibiting SNARE complex formation and neurotransmitter release at the neuromuscular junction — a topical Botox-like mechanism. Shows 30% reduction in wrinkle depth after 30 days.

Citation

Journal
International Journal of Cosmetic Science
Year
2002
DOI
10.1046/j.1467-2494.2002.00153.x
View on DOI.org

Key Findings

1

30% reduction in wrinkle depth after 30 days of twice-daily topical application

2

Mechanism: competitive inhibition of SNARE complex, reducing acetylcholine release

3

Reduces facial muscle contraction without systemic effects or injection

4

Synergistic effects with other anti-aging peptides (Leuphasyl, Matrixyl)

5

Well-tolerated with no significant adverse effects in clinical studies

Methodology

Double-blind placebo-controlled clinical study with silicone replica wrinkle depth measurement. In vitro SNARE complex inhibition assays and neuromuscular junction studies.

Limitations

Effect size smaller than injectable botulinum toxin. Topical penetration limits efficacy. Results may vary by formulation and skin type.

Tags

ArgirelineAcetyl Hexapeptide-3WrinkleSNAREAnti-agingTopicalCosmetic

Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.

Build a protocol around this research

Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.

Start Assessment